Transaction · 0002007659-26-000002
KZRKezar Life Sciences, Inc.
Schiller Mark C.
Schiller Mark C., COO, reported a transaction classified as unknown at Kezar Life Sciences, Inc. involving 2739.000000 shares. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
unknownSEC transaction code UCOO
- Trade date
- May 11, 2026
- Filing date
- May 11, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
Filing warnings
Notes recorded with this filingmissing priceThe filing did not provide a usable price per share.
KZR price since this filing
Daily closing prices, with the filing date and available return windowsKZR · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y
Transaction facts
Stored Form 4 columns with their raw values
- Type
- unknown Code U
- Identifier
- 0002007659-26-000002 Common Stock
- Transaction date
- May 11, 2026 Filed May 11, 2026, 08:30 PM · 0d delay
- Shares
- 2,739 sh Price unknown
- Estimated value
- — Computed from shares × price
- Holdings after
- 0 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership
Filing-only score
+2 points
Compact filing score computed from stored Form 4 facts. Version v1.
Neutral filing signal
This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 0
Filing reported within two business days of the transaction. - missing_price-8 points
price_cents is null
Missing price reduces confidence in value-based signals.
Missing facts
Read the scoring methodology- price_cents
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Reported roles
Chief Operating Officer
Officer YesDirector No10% NoOther No
Footnotes & amended
- F1
In connection with the terms of an Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), by and among the Issuer, Aurinia Pharma U.S., Inc. ("Parent") and Parent's direct…
("Purchaser"), Purchaser completed a tender offer for shares of the Issuer's Common Stock. In exchange for each share, tendering stockholders received: (i) $6.955 per share in cash, without interest a…
- F2
(continued from footnote 1) without interest and less any applicable tax withholding, upon the achievement of specified milestones in accordance with the terms and subject to the conditions of a CVR A…
Parent (the "Effective Time").
- F3
Pursuant to the terms of the Merger Agreement, each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than the Cash…
- F4
Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and conver…
Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option.
Related transactions
Same SEC filing0 other transactions
Recent company activity
KZR0 recent txs